Document is current

Article History

Received: 24 July 2025

Accepted: 11 November 2025

First Online: 10 January 2026

Declarations

:

: The study was performed in accordance with relevant guidelines and followed the principles of the Helsinki Declaration of 1964 and subsequent revisions. The research was submitted to the Pearl Institutional Review Board, study protocol number #22-ADRW-162.Using a checkbox, caregivers provided informed consent to take part in the survey. Data were collected in such a way that patients, caregivers and physicians could not be identified directly. Data related to physicians, caregivers and people with DMD were pseudo-anonymized. A code was assigned when data were collected. Upon receipt by ARW, data were pseudo-anonymized again to mitigate against tracing them back to the individual. Data were aggregated before being shared with the subscriber and/or for publication.

: Not applicable.

: JS is on the advisory board for Sarepta, speaker training for NS Pharma, was PI for Fibrogen pamrevlumab phase 2 trial and currently PI for PTC ataluaren phase 3. JS is also a speaker bureau for Biogen, consultant for UCB and Janssen/Momenta, and PI for Janssen and Alexion. KI received honoraria for speakers bureaus from Nippon Shinyaku Co., Ltd and has an advisory role at Pfizer Japan Inc. JCC and NP are employees and stockholders of Pfizer Inc. SX, AT and SD are employees of Pfizer and may own stocks/shares of the company. EC, EM, SW and JdC are full-time employees of Adelphi Real World, which received funding from Pfizer in connection with the development of this manuscript. HI no longer works for Adelphi Real World but did at the time of writing.